

**RECEIVED**

OCT 24 2002

TECH CENTER 1600/2900

PATENT

Atty. Docket No.: Le A 34 494

#9

MP  
11/07/02**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**APPLICANTS: Böb, *et al.*

SERIAL NO.: 09/911,277

EXAMINER: M. Bahar

FILING DATE: July 23, 2001

ART UNIT: 1617

TITLE: Selective PDE2 Inhibitors as Pharmaceuticals for Improving Perception

**RESPONSE**Assistant Commissioner for Patents  
Washington, D.C. 20231

CERTIFICATE OF MAILING OF U.S. C.F.R. § 1.8  
The undersigned hereby certifies that this paper and any papers referred to as attached is/are being deposited with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on this 4th day of OCTOBER, 2002.

Signature of Person Certifying

Sir:

This Response is submitted in the above-captioned application in response to the Office Action mailed from the Patent Office on May 21, 2002. A two-month extension of time in which to respond to the Office Action is respectfully requested. A Petition and Fee for extending the response period two months, up to and including October 21, 2002, is enclosed.

Remarks

Claims 1 and 3-9 are pending in the application. Claims 1 and 3-9 are rejected under 35 U.S.C. § 103(a). This rejection is traversed to the extent it is maintained over the arguments below.

Section 103(a)

Claims 1 and 3-9 are rejected under 35 U.S.C. § 103(a) as being obvious in light of Haning (US 6,174,884). Haning describes a general class of compounds that are inhibitors of PDE1, 2 and/or 5 that are useful in treating various disorders, including cerebrovascular disorders. No specific cerebrovascular disorders are described by